A recent study indicates that patients who come off blockbuster slimming jabs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who halt traditional diet and exercise regimens.
Findings released in a leading health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Individuals buying these medications must be aware of the danger of fast weight regain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
That rate of regain means a reversion to starting weight within about one and a half years.
Weighing Approaches
The analysis, which reviewed dozens of studies involving thousands of patients, compared the outcomes of the injectable medications with older methods.
The team point out that people who shed pounds through diet and exercise usually experience a more gradual weight regain—around 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Nutrition scientists believe the mechanism of the jabs explains the amplified rebound.
These medications imitate a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels far above than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating much more probable."
An Ongoing Condition?
The NHS suggest the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.
A number of clinicians say that, due to the significant potential of relapse, the therapy is often long-term.
This perspective is supported by drug manufacturers, who note that the results "highlight the persistent character of obesity," comparing it to managing diseases like hypertension.
Patient Testimonies
Individuals who have stopped the medication report a intense return of cravings.
"It was like a switch activating and I was suddenly ravenous," described an individual.
The struggle is exacerbated if patients have not established lasting lifestyle or habit changes during treatment.
Growing Use
Recent estimates indicate that millions of adults in the UK have used these injections in the last 12 months, with demand remaining high.
- Adoption is greater among women than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent fix and lasting health benefits hinges on combined lifestyle changes.
